S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
NASDAQ:VERV

Verve Therapeutics (VERV) Stock Forecast, Price & News

$13.26
+0.30 (+2.31%)
(As of 09/29/2023 ET)
Compare
Today's Range
$12.79
$13.47
50-Day Range
$11.42
$20.74
52-Week Range
$11.25
$40.88
Volume
985,181 shs
Average Volume
718,416 shs
Market Capitalization
$844.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.83

Verve Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
132.5% Upside
$30.83 Price Target
Short Interest
Bearish
27.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Verve Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.50) to ($3.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

869th out of 972 stocks

Pharmaceutical Preparations Industry

413th out of 454 stocks


VERV stock logo

About Verve Therapeutics (NASDAQ:VERV) Stock

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV Price History

VERV Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Verve Therapeutics Names Frederick Fiedorek CMO
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Cracking The Cholesterol Code: Verve's High-Stakes Bet
1 Cathie Wood Stock That Could Go Parabolic Soon
Cantor Fitzgerald Keeps Their Hold Rating on Verve Therapeutics (VERV)
Expert Ratings for Verve Therapeutics
See More Headlines
Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERV Company Calendar

Last Earnings
8/10/2023
Today
10/01/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VERV
Fax
N/A
Employees
204
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.83
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+132.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-157,390,000.00
Net Margins
-3,534.98%
Pretax Margin
-3,530.78%

Debt

Sales & Book Value

Annual Sales
$1.94 million
Book Value
$8.94 per share

Miscellaneous

Free Float
50,085,000
Market Cap
$844.93 million
Optionable
Not Optionable
Beta
1.70
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Burt A. Adelman M.D. (Age 71)
    Co-Founder & Independent Chairman
    Comp: $87.55k
  • Dr. Sekar Kathiresan M.D. (Age 51)
    Co-Founder, CEO & Director
    Comp: $899.55k
  • Mr. Andrew D. Ashe J.D.Mr. Andrew D. Ashe J.D. (Age 56)
    Pres, COO & Gen. Counsel
    Comp: $703.85k
  • Dr. Andrew Bellinger M.D. (Age 45)
    Ph.D., Chief Scientific Officer & Chief Medical Officer
    Comp: $703.85k
  • Dr. Kiran Musunuru M.D.
    M.P.H., Ph.D., Co-Founder & Sr. Scientific Advisor
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder
  • Dr. Anthony Philippakis M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. Barry S. Ticho FACC (Age 62)
    M.D., Ph.D., Co-Founder
  • Mr. Issi Rozen M.B.A.
    Co-Founder & Strategic Advisor
  • Ms. Allison Dorval (Age 47)
    CFO & Principal Accounting Officer













VERV Stock - Frequently Asked Questions

Should I buy or sell Verve Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VERV shares.
View VERV analyst ratings
or view top-rated stocks.

What is Verve Therapeutics' stock price forecast for 2023?

8 brokers have issued 1 year price objectives for Verve Therapeutics' shares. Their VERV share price forecasts range from $13.00 to $55.00. On average, they predict the company's share price to reach $30.83 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price.
View analysts price targets for VERV
or view top-rated stocks among Wall Street analysts.

How have VERV shares performed in 2023?

Verve Therapeutics' stock was trading at $19.35 at the beginning of the year. Since then, VERV shares have decreased by 31.5% and is now trading at $13.26.
View the best growth stocks for 2023 here
.

When is Verve Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our VERV earnings forecast
.

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.03. The firm earned $2.10 million during the quarter, compared to analysts' expectations of $0.67 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 37.08% and a negative net margin of 3,534.98%. The business's revenue for the quarter was up 2000.0% compared to the same quarter last year.

When did Verve Therapeutics IPO?

(VERV) raised $201 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.

What is Verve Therapeutics' stock symbol?

Verve Therapeutics trades on the NASDAQ under the ticker symbol "VERV."

How do I buy shares of Verve Therapeutics?

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verve Therapeutics' stock price today?

One share of VERV stock can currently be purchased for approximately $13.26.

How much money does Verve Therapeutics make?

Verve Therapeutics (NASDAQ:VERV) has a market capitalization of $844.93 million and generates $1.94 million in revenue each year. The company earns $-157,390,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis.

How many employees does Verve Therapeutics have?

The company employs 204 workers across the globe.

How can I contact Verve Therapeutics?

The official website for the company is vervetx.com. The company can be reached via phone at 617-603-0070 or via email at ir@vervetx.com.

This page (NASDAQ:VERV) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -